FGF19-FGFR4 Signaling in Hepatocellular Carcinoma

被引：122

作者：

Raja, Aroosha ^{[1
]}

Park, Inkeun ^{[2
]}

Haq, Farhan ^{[1
]}

Ahn, Sung-Min ^{[2
,3
]}

机构：

[1] Comsats Univ, Dept Biosci, Islamabad 45550, Pakistan

[2] Gachon Univ, Dept Internal Med, Div Med Oncol, Gil Med Ctr, Incheon 21565, South Korea

[3] Gachon Univ, Coll Med, Dept Genome Med & Sci, Incheon 21565, South Korea

来源：

CELLS | 2019年 / 8卷 / 06期

关键词：

prognosis; FGF19; FGFR4; HCC; inhibitors; FIBROBLAST-GROWTH-FACTOR; FGFR4 GLY388ARG POLYMORPHISM; FACTOR RECEPTOR; FGF19; EXPRESSION; SORAFENIB; CANCER; KLOTHO; LIVER; INHIBITOR;

D O I：

10.3390/cells8060536

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Hepatocellular carcinoma (HCC) is the sixth most common type of cancer, with an increasing mortality rate. Aberrant expression of fibroblast growth factor 19-fibroblast growth factor receptor 4 (FGF19-FGFR4) is reported to be an oncogenic-driver pathway for HCC patients. Thus, the FGF19-FGFR4 signaling pathway is a promising target for the treatment of HCC. Several pan-FGFR (1-4) and FGFR4-specific inhibitors are in different phases of clinical trials. In this review, we summarize the information, recent developments, binding modes, selectivity, and clinical trial phases of different available FGFR4/pan-FGF inhibitors. We also discuss future perspectives and highlight the points that should be addressed to improve the efficacy of these inhibitors.

引用

页数：16

共 74 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2] Genomic Portrait of Resectable Hepatocellular Carcinomas: Implications of RB1 and FGF19 Aberrations for Patient Stratification [J].

Ahn, Sung-Min ;

Jang, Se Jin ;

Shim, Ju Hyun ;

Kim, Deokhoon ;

Hong, Seung-Mo ;

Sung, Chang Ohk ;

Baek, Daehyun ;

Haq, Farhan ;

Ansari, Adnan Ahmad ;

Lee, Sun Young ;

Chun, Sung-Min ;

Choi, Seongmin ;

Choi, Hyun-Jeung ;

Kim, Jongkyu ;

Kim, Sukjun ;

Hwang, Shin ;

Lee, Young-Joo ;

Lee, Jong-eun ;

Jung, Wang-rim ;

Jang, Hye Yoon ;

Yang, Eunho ;

Sung, Wing-Kin ;

Lee, Nikki P. ;

Mao, Mao ;

Lee, Charles ;

Zucman-Rossi, Jessica ;

Yu, Eunsil ;

Lee, Han Chu ;

Kong, Gu .

HEPATOLOGY, 2014, 60 (06) :1972-1982

[3] Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma [J].

Ally, Adrian ;

Balasundaram, Miruna ;

Carlsen, Rebecca ;

Chuah, Eric ;

Clarke, Amanda ;

Dhalla, Noreen ;

Holt, Robert A. ;

Jones, Steven J. M. ;

Lee, Darlene ;

Ma, Yussanne ;

Marra, Marco A. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Andrew J. ;

Schein, Jacqueline E. ;

Sipahimalani, Payal ;

Tam, Angela ;

Thiessen, Nina ;

Cheung, Dorothy ;

Wong, Tina ;

Brooks, Denise ;

Robertson, A. Gordon ;

Bowlby, Reanne ;

Mungall, Karen ;

Sadeghi, Sara ;

Xi, Liu ;

Covington, Kyle ;

Shinbrot, Eve ;

Wheeler, David A. ;

Gibbs, Richard A. ;

Donehower, Lawrence A. ;

Wang, Linghua ;

Bowen, Jay ;

Gastier-Foster, Julie M. ;

Gerken, Mark ;

Helsel, Carmen ;

Leraas, Kristen M. ;

Lichtenberg, Tara M. ;

Ramirez, Nilsa C. ;

Wise, Lisa ;

Zmuda, Erik ;

Gabriel, Stacey B. ;

Meyerson, Matthew ;

Cibulskis, Carrie ;

Murray, Bradley A. ;

Shih, Juliann ;

Beroukhim, Rameen ;

Cherniack, Andrew D. ;

Schumacher, Steven E. ;

Saksena, Gordon .

CELL, 2017, 169 (07) :1327-+

[4]

[Anonymous], HUMAN FETAL TISSUE T

[5] U3-1784, a human anti-FGFR4 antibody for the treatment of cancer [J].

Bartz, Rene ;

Fukuchi, Keisuke ;

Lange, Tanja ;

Gruner, Katrin ;

Ohtsuka, Toshiaki ;

Watanabe, Ichiro ;

Hayashi, Shinko ;

Redondo-Mueller, Mauricio ;

Takahashi, Mizuki ;

Agatsuma, Toshinori ;

Bange, Johannes ;

Abraham, Reimar .

CANCER RESEARCH, 2016, 76

[6] Discovery of the highly selective covalent FGFR1-4 inhibitor PRN1371 currently in development for the treatment of solid tumors [J].

Brameld, Ken A. .

CANCER RESEARCH, 2016, 76

[7] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[8]

Chen Z., 2018, CANCER RES, V78, pLB, DOI [10.1158/1538-7445.Am2018-lb-272, DOI 10.1158/1538-7445.AM2018-LB-272]

[9] Anti-FGFR4 antibody drug conjugate for immune therapy of rhabdomyosarcoma and hepatocellular carcinoma [J].

Cheuk, Adam ;

Shivaprasad, Nitya ;

Skarzynski, Martin ;

Baskar, Sivasubramanian ;

Azorsa, Peter ;

Khan, Javed .

CANCER RESEARCH, 2018, 78 (13)

[10] Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver [J].

Cui, Guozhen ;

Martin, Robert C. ;

Jin, Hang ;

Liu, Xingkai ;

Pandit, Harshul ;

Zhao, Hengjun ;

Cai, Lu ;

Zhang, Ping ;

Li, Wei ;

Li, Yan .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37

← 1 2 3 4 5 6 7 8 →